title: [A case of paclitaxel-induced peripheral neuropathy successfully treated by H2-blocker, lafutidine].
abstract: We report a 75-year-old female gastric cancer patient with paclitaxel-induced peripheral neuropathy, which was successfully treated by the H2-blocker, lafutidine. From December 2007, she underwent second-line chemotherapy using paclitaxel (80 mg/m/2 day 1, 7, 14/28 days) for peritoneal dissemination which had been refractory to first-line chemotherapy using S-1 (80 mg/m / 2, day 1-28/42 days). After 2 courses, CT showed a complete response (CR) of the peritoneal dissemination. However, at the same time peripheral neuropathy appeared, which was aggravated to grade 3 at the 6th course. Beginning with the 7th course, we administered lafutidine (10 mg/day) for peripheral neuropathy, which recovered to grade 1 after 14 days of lafutidine administration. Lafutidine was administered until July 2008, when peripheral neuropathy kept grade 1 without lafutidine. After 9 courses, paclitaxel therapy failed because of general fatigue.
authors.affiliation: Dept. of Surgery, Sakai Municipal Hospital.
authors.forename: Tae
authors.initials: T
authors.lastname: Matsumura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Misako
authors.initials: M
authors.lastname: Fujino
authors.forename: Yukako
authors.initials: Y
authors.lastname: Yasui
authors.forename: Setsuko
authors.initials: S
authors.lastname: Anami
authors.forename: Rumi
authors.initials: R
authors.lastname: Sumita
authors.forename: Natsuko
authors.initials: N
authors.lastname: Takada
authors.forename: Yuuko
authors.initials: Y
authors.lastname: Fujita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D000081:Acetamides; D000972:Antineoplastic Agents, Phytogenic; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; C076948:lafutidine; D017239:Paclitaxel